CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer

BACKGROUND: The identification of high-risk stage II colon cancers is key to the selection of patients who require adjuvant treatment after surgery. Microarray-based multigene-expression signatures derived from stem cells and progenitor cells hold promise, but they are difficult to use in clinical p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Autores principales: Dalerba, Piero, Sahoo, Debashis, Paik, Soonmyung, Guo, Xiangqian, Yothers, Greg, Song, Nan, Wilcox-Fogel, Nate, Forgó, Erna, Rajendran, Pradeep S., Miranda, Stephen P., Hisamori, Shigeo, Hutchison, Jacqueline, Kalisky, Tomer, Qian, Dalong, Wolmark, Norman, Fisher, George A., van de Rijn, Matt, Clarke, Michael F.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4784450/
https://ncbi.nlm.nih.gov/pubmed/26789870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1506597
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares